Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/21907257/ below:

Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink

Affiliations

• ¹ Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. jgee@cdc.gov

• PMID: 21907257
• DOI: 10.1016/j.vaccine.2011.08.106

Item in Clipboard

Julianne Gee et al. Vaccine. 2011.

• ¹ Division of Healthcare Quality and Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. jgee@cdc.gov

• PMID: 21907257
• DOI: 10.1016/j.vaccine.2011.08.106

Item in Clipboard

Background: In 7 large managed care organizations (MCOs), we performed a post-licensure safety assessment of quadrivalent human papillomavirus vaccine (HPV4) among 9-26 year-old female vaccine recipients between August 2006 and October 2009.

Methods: Sequential analyses were conducted weekly to detect associations between HPV4 exposure and pre-specified outcomes. The pre-specified outcomes identified by ICD-9 codes using computerized data at the participating MCOs included: Guillan-Barré Syndrome (GBS), stroke, venous thromboembolism (VTE), appendicitis, seizures, syncope, allergic reactions, and anaphylaxis. For rare outcomes, historical background rates were used as the comparison group. For more common outcomes, a concurrent unexposed comparison group was utilized. A standardized review of medical records was conducted for all cases of GBS, VTE, and anaphylaxis.

Results: A total of 600,558 HPV4 doses were administered during the study period. We found no statistically significant increased risk for the outcomes studied. However, a non-statistically significant relative risk (RR) for VTE ICD-9 codes following HPV4 vaccination of 1.98 was detected among females age 9-17 years. Medical record review of all 8 vaccinated potential VTE cases in this age group revealed that 5 met the standard case definition for VTE. All 5 confirmed cases had known risk factors for VTE (oral contraceptive use, coagulation disorders, smoking, obesity or prolonged hospitalization).

Conclusions: In a study of over 600,000 HPV4 vaccine doses administered, no statistically significant increased risk for any of the pre-specified adverse events after vaccination was detected. Further study of a possible association with VTE following HPV4 vaccination is warranted.

Published by Elsevier Ltd.

PubMed Disclaimer

• Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females.

  Yih WK, Greene SK, Zichittella L, Kulldorff M, Baker MA, de Jong JL, Gil-Prieto R, Griffin MR, Jin R, Lin ND, McMahill-Walraven CN, Reidy M, Selvam N, Selvan MS, Nguyen MD. Yih WK, et al. Vaccine. 2016 Jan 2;34(1):172-8. doi: 10.1016/j.vaccine.2015.09.087. Epub 2015 Nov 6. Vaccine. 2016. PMID: 26549364

• Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.

  Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, Greene SK, Harrington T, Jackson LA, Klein NP, Tseng HF, Vellozzi C, Weintraub ES; Vaccine Safety Datalink. Naleway AL, et al. Vaccine. 2016 Jan 2;34(1):167-71. doi: 10.1016/j.vaccine.2015.10.006. Epub 2015 Nov 6. Vaccine. 2016. PMID: 26549361 Free PMC article.

• Adverse events following immunization in Ontario's female school-based HPV program.

  Harris T, Williams DM, Fediurek J, Scott T, Deeks SL. Harris T, et al. Vaccine. 2014 Feb 19;32(9):1061-6. doi: 10.1016/j.vaccine.2014.01.004. Epub 2014 Jan 15. Vaccine. 2014. PMID: 24440208

• An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.

  Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, Sings HL, Perez G, Haupt RM, Saah AJ, Lievano F, Velicer C, Drury R, Kuter BJ. Vichnin M, et al. Pediatr Infect Dis J. 2015 Sep;34(9):983-91. doi: 10.1097/INF.0000000000000793. Pediatr Infect Dis J. 2015. PMID: 26107345 Review.

• Allergic reactions to Japanese encephalitis vaccine.

  Plesner AM. Plesner AM. Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. doi: 10.1016/s0889-8561(03)00102-4. Immunol Allergy Clin North Am. 2003. PMID: 14753386 Review.

• Safety of human papillomavirus vaccines: a review.

  Stillo M, Carrillo Santisteve P, Lopalco PL. Stillo M, et al. Expert Opin Drug Saf. 2015 May;14(5):697-712. doi: 10.1517/14740338.2015.1013532. Epub 2015 Feb 18. Expert Opin Drug Saf. 2015. PMID: 25689872 Free PMC article. Review.

• Vaccine against human papilloma virus.

  Reina JC, Muñoz N. Reina JC, et al. Colomb Med (Cali). 2014 Sep 30;45(3):94-5. eCollection 2014 Jul-Sep. Colomb Med (Cali). 2014. PMID: 25386033 Free PMC article. No abstract available.

• Safety of Human Papillomavirus Vaccines: An Updated Review.

  Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Phillips A, et al. Drug Saf. 2018 Apr;41(4):329-346. doi: 10.1007/s40264-017-0625-z. Drug Saf. 2018. PMID: 29280070 Review.

• Adolescent Attitudes Toward the Human Papillomavirus (HPV) Vaccine in Kocaeli, Turkiye.

  Gundogdu MY, Gezer MZ, Gundogdu Z. Gundogdu MY, et al. Cureus. 2025 Feb 9;17(2):e78760. doi: 10.7759/cureus.78760. eCollection 2025 Feb. Cureus. 2025. PMID: 40070638 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3